Author: Matthew

Montana lawmakers are exploring ways to regulate kratom before the 2027 legislative session amid growing concern over synthetic versions of the drug. Use of both natural and synthetic kratom products has surged nationwide in recent decades, prompting 18 states to regulate manufacturing and sales and six to classify certain compounds as controlled substances as of April 2025.

Montana has no statewide laws on kratom, a gap members of the Law and Justice Interim Committee highlighted during a Jan. 14 hearing. A 2025 bill to restrict high levels of 7-hydroxymitragynine and bar sales to those under 21 stalled in committee, leaving regulation to local governments such as the Blackfeet Tribal Business Council and Yellowstone County. Lawmakers plan to reconvene in March after studying approaches in other states, including an emergency 180-day ban on synthetic kratom by the Ohio Board of Pharmacy. Read the original report at the Daily Inter Lake.

The American Kratom Association (AKA) has criticized the Ohio Board of Pharmacy for its unanimous decision to classify natural kratom’s key compound, mitragynine, as a controlled substance — a move the group calls “scientifically unjustified.”

In a statement, the AKA expressed deep concern that the Board reached its decision “without a single question” during deliberations, relying on what it described as outdated federal data long rejected by health officials. Both HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Dr. Marty Makary have clarified that enforcement should target synthetic 7-hydroxymitragynine products, not natural kratom leaf. The AKA has urged Ohio lawmakers to intervene and reverse the decision, calling it a threat to consumers who use kratom as a safer alternative to opioids.

Read the full statement from the American Kratom Association.

The Berkeley County Coroner’s Office in South Carolina will hold a public forum on Tuesday to discuss kratom, a plant-based substance often used for pain relief and anxiety. The event, hosted in partnership with the Ernest E. Kennedy Center and Wake Up Carolina, aims to give residents a clearer understanding of kratom’s local impact and the latest medical findings surrounding its use.

While some people use kratom to manage pain or opioid withdrawal, the U.S. Food and Drug Administration warns it is not approved as a dietary supplement. The free town hall will include expert-led discussions and community data.

Read more via MSN News.

New York Governor Kathy Hochul has signed two new laws regulating the sale and labeling of kratom, a psychoactive plant-based substance. The legislation bans sales to anyone under 21 and requires warning labels stating possible health risks, including agitation, liver damage, and death. Advertising kratom as “all-natural” is also prohibited.

The new laws follow advocacy from Saratoga County resident Cari Scribner, whose son Nickolas died in 2024 after using the substance. Hochul credited Scribner’s efforts in pushing the legislation forward, calling her a “fierce advocate” for public health.

Violators face fines up to $500 for retailers and $1,000 for manufacturers. The labeling requirements take effect in 2026. Full story available at Saratoga TODAY.

New York State has introduced stricter controls on kratom, an herbal product often marketed as a natural stimulant or pain reliever. Governor Kathy Hochul signed two bills aimed at improving public safety and product transparency. The first measure bans sales of kratom to anyone under 21, with fines up to $500 per offense. The second requires all kratom products to display warning labels outlining addiction risks, possible drug interactions, and a full list of ingredients.

Health officials warn that concentrated forms of kratom, or products adulterated with synthetic compounds, can act like opioids and pose serious health risks. The New York State Department of Health will begin monitoring these substances more closely.

Read the full story at Sun Community News.

Fresno city officials have reversed course on a proposed kratom ban, instead approving an ordinance that permits the sale of natural-leaf kratom to adults while banning concentrated derivatives. Under the new law, taking effect in January 2026, retailers may sell kratom products only to customers aged 21 and over, provided levels of the psychoactive compound 7-hydroxymitragynine (7-OH) remain below 1% of total alkaloids.

Councilmember Nelson Esparza, who introduced the amendment, said the goal was to balance public safety with respect for kratom’s traditional cultural use. Fresno County is considering a similar policy with a 2% 7-OH limit.

Read the full report by Tim Sheehan via KVPR.

DENVER – Colorado’s new Daniel Bregger Act is reshaping the conversation around kratom by tightening safety rules without banning the herbal supplement that many users credit with easing pain and opioid withdrawal. The law caps highly concentrated 7-hydroxymitragynine products, restricts sales to adults over 21 and requires clearer labeling, moves designed to steer consumers toward traditional leaf-based kratom and away from risky gas-station style shots.​

Researchers, backed by multimillion-dollar NIH funding, are simultaneously probing kratom’s alkaloids as candidates for safer pain medicines and treatments for opioid dependence. Early work suggests some compounds may relieve pain and withdrawal with less danger of respiratory depression, strengthening calls to regulate, not prohibit, kratom. A fuller exploration of these developments appears in The Conversation’s analysis.

As Los Angeles County health officials move to ban the sale of kratom and synthetic 7-OH, advocates warn that sweeping prohibition may not be the answer. In a recent letter to the editor, Yael Ossowski of the Consumer Choice Center argues that states like Rhode Island have shown a better path—enacting dosage standards, labeling requirements, and age restrictions, rather than criminalizing millions of users. Ossowski highlights that overdose cases linked to kratom and 7-OH often involve multiple substances, making transparent market rules more essential than ever. The letter urges policymakers to focus on safe regulation instead of outright bans, promoting consumer safety and clarity. Read the original letter in the Los Angeles Times for further details.

Governor Andy Beshear has announced a new measure targeting 7-hydroxymitragynine (7-OH), a synthetic and concentrated derivative of the kratom plant, by classifying it as a Schedule I narcotic in Kentucky. The move makes it illegal to sell, possess, or distribute any isolated or concentrated forms of 7-OH, a substance with the potential for abuse due to its strong binding to opioid receptors.

Officials emphasized that this action is aimed at protecting public health and sustaining progress in reducing overdose deaths—Kentucky has seen declines for three consecutive years. Importantly, while 7-OH occurs naturally in kratom in small amounts, it is the concentrated, synthetic versions in products like shots, powders, or capsules that are now under scrutiny. The new regulation does not target natural kratom, only these potent derivatives.

For more details, see the original reporting at LEX18.com.

Toledo officials have unanimously approved a local ordinance banning the sale of synthetic kratom products, stepping up efforts to control lab-made versions of the herbal supplement. Council member Sam Melden, who championed the proposal, noted that naturally sourced kratom leaves remain unaffected by the restriction pending further study.

“This measure focuses squarely on synthetic and derivative forms sold in shops across the city,” Melden explained.

The council’s decision aligns with broader discussions at the state level, as Governor Mike DeWine continues to press for tighter kratom oversight across Ohio. Traditional kratom, derived from a Southeast Asian plant, is still legal and commonly used for pain relief, mood support, and managing withdrawal symptoms.

Full article available at MSN News.

Natural leaf kratom should not be conflated with its potent synthetic derivatives, says Dr. C. Michael White, a University of Connecticut pharmacy professor and chair of the Kratom Consumer Advisory Council. In his recent Hartford Courant opinion piece, White stresses that while synthetic opioids derived from kratom’s alkaloids—such as 7-hydroxymitragynine—pose serious addiction risks, natural kratom leaves have a much milder pharmacological profile. The council supports Connecticut’s proposed framework requiring product registration, lab certification, and age restrictions, ensuring consumer safety without restricting access for responsible adult users. White argues that maintaining legal access to natural kratom may offer a safer alternative for those managing chronic pain or opioid dependence, provided appropriate safeguards are in place.